Clinical Scorecard: A New Predictive Model for Kidney Failure in Chronic Kidney Disease Patients: The Role of Serum Bilirubin Concentrations
At a Glance
Category
Detail
Condition
Chronic Kidney Disease (CKD) progressing to End-Stage Kidney Disease (ESKD)
Key Mechanisms
Serum bilirubin as a potent antioxidant and anti-inflammatory molecule inversely associated with CKD progression; oxidative stress contributes to CKD progression
Target Population
Adults aged 20-69 years with CKD (eGFR 15-60 mL/min/1.73 m2) without baseline dialysis, transplantation, acute kidney injury, or hemolytic anemia
Care Setting
Hospital-based nephrology care in Japan (Kyushu University Hospital and National Hospital Organization Kyushu Medical Center)
Key Highlights
Serum bilirubin levels are strong independent predictors of progression from CKD to ESKD.
A novel prediction model incorporating nine variables including serum bilirubin demonstrated excellent discrimination (2-year AUC: 0.943; 5-year AUC: 0.935) and calibration.
The model was validated externally in an independent cohort, confirming its predictive accuracy.
Guideline-Based Recommendations
Diagnosis
Assess CKD stage using eGFR and proteinuria.
Measure serum bilirubin levels as part of risk stratification for CKD progression.
Management
Incorporate serum bilirubin levels alongside traditional risk factors (age, gender, eGFR, proteinuria, diabetes, hypertension, serum albumin, hemoglobin) to guide prognosis and management.
Monitor and manage modifiable risk factors such as diabetes and hypertension to slow CKD progression.
Monitoring & Follow-up
Regular follow-up with at least 5 eGFR measurements over time to track kidney function decline.
Monitor serum bilirubin levels as a potential biomarker for risk assessment.
Risks
Low serum bilirubin levels may indicate higher risk of progression to ESKD.
Exclude confounding conditions such as hemolytic anemia that affect bilirubin levels.
Patient & Prescribing Data
CKD patients aged 20-69 years with eGFR between 15 and 60 mL/min/1.73 m2, excluding those on dialysis or with renal transplantation.
Inclusion of serum bilirubin levels in risk prediction models may improve individualized patient prognostication and inform treatment intensity decisions.
Clinical Best Practices
Use a multi-variable risk prediction model including serum bilirubin to accurately predict CKD progression to ESKD.
Ensure comprehensive baseline assessment including eGFR, proteinuria, serum bilirubin, and other clinical variables.
Validate prediction models in independent cohorts before clinical application.
Exclude patients with conditions affecting bilirubin metabolism when interpreting bilirubin levels for risk prediction.
